Clinical trials: in Egypt
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.
- Trial name
- iCHOROS (NCT07069829)
- Where
- 36 sites in Argentina, Colombia and 10 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Neurofibromatosis Type 1
Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
Neurofibromatosis type 1 (NF1), a genetic disorder, results from NF1 gene mutations with nearly complete penetrance (1). NF1 is considered common as a rare disease; it has a birth incidence of approximately one every 3000 and a…
- Trial name
- PRECIOUS Egypt (NCT07221331)
- Where
- 9 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Hypertension
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
- Conditions
- Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
- Trial name
- iCaReMe (NCT03549754)
- Where
- 76 sites in Brazil, Chile and 18 more
- Volunteers
- 35,000 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus (SLE)
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients.
- Trial name
- INTERSTELLAR (NCT06314282)
- Where
- 32 sites in Argentina, China and 10 more
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Warm Autoimmune Hemolytic Anemia
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
- Trial name
- ENERGY (NCT04119050)
- Testing
- M281
- Where
- 171 sites in United States, Brazil and 17 more
- Volunteers
- 118 people
- Sponsor
- Janssen Research & Development, LLC
Osteo Arthritis Knee, Varus Knee
The Effect of Body Mass Index on Short-term Results of HTO
The knee joint plays a major role in weight transmission of the body in day-to-day activities. The biomechanics of the knee and malalignment in lower limb anatomy are major risk factors for chronic knee pain, leaving Total Knee…
- Trial name
- NCT06590818
- Testing
- High tibial osteotomy (HTO
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Egymedicalpedia
Unresectable Hepatocellular Carcinoma
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with…
- Trial name
- IMbrave251 (NCT04770896)
- Testing
- Atezolizumab, Lenvatinib, Sorafenib
- Where
- 124 sites in Austria, Belgium and 26 more
- Volunteers
- 557 people
- Sponsor
- Hoffmann-La Roche
Lung Malignancy
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
Artificial intelligence (AI) based algorithms have demonstrated increased accuracy in predicting the risk of Lung Cancer among patients with an incidental pulmonary nodule (IPN) on chest radiographs.
- Trial name
- CREATE (NCT05817110)
- Testing
- Participant Cohort
- Where
- 22 sites in Egypt, India and 3 more
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Atypical Hemolytic Uremic Syndrome
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases per million population per year.
- Trial name
- REACH (NCT07218536)
- Where
- 6 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Crohn's Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
The study consists of 4 sub-studies, as follows: Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with…
- Trial name
- FORTIFY (NCT03105102)
- Testing
- Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI)
- Where
- 496 sites in United States, Argentina and 45 more
- Volunteers
- 1,336 people
- Sponsor
- AbbVie
Urothelial Carcinoma, Non-Small Cell Lung Cancer
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes…
- Conditions
- Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- IMreal (NCT03782207)
- Testing
- Atezolizumab
- Where
- 257 sites in Argentina, Austria and 28 more
- Volunteers
- 2,756 people
- Sponsor
- Hoffmann-La Roche
Severe Aortic Valve Stenosis
The Use of ACURATE Neo 2 Valve in Patients With Symptomatic Aortic Valve Stenosis
The objective of this study is to evaluate the ACURATE Neo2 in the Middle East population with severe, symptomatic aortic stenosis.
- Trial name
- BSC07 (NCT05847751)
- Testing
- Aortic valve replacement
- Where
- 7 sites in Egypt, Lebanon and 1 more
- Volunteers
- 51 people
- Sponsor
- Ceric Sàrl
Progressive Multiple Sclerosis (PMS)
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
- Trial name
- CONSONANCE (NCT03523858)
- Testing
- Ocrelizumab
- Where
- 120 sites in United States, Bosnia and Herzegovina and 22 more
- Volunteers
- 927 people
- Sponsor
- Hoffmann-La Roche
Open-Angle Glaucoma, Ocular Hypertension
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091…
- Trial name
- MAIA (NCT03891446)
- Testing
- Bimatoprost SR, Standard of Care
- Where
- 124 sites in United States, Argentina and 24 more
- Volunteers
- 455 people
- Sponsor
- AbbVie
Growth Hormone Deficiency (GHD)
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
A six month study of ACP-001, a long-acting growth hormone product, versus standard human growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone (hGH) will be given on a daily basis.
- Trial name
- NCT01947907
- Testing
- ACP-001, Human Growth Hormone
- Where
- 36 sites in Belarus, Bulgaria and 12 more
- Volunteers
- 53 people
- Sponsor
- Ascendis Pharma A/S
Crohn's Disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are…
- Trial name
- CULTIVATE (NCT04173273)
- Testing
- Etrasimod
- Where
- 510 sites in United States, Argentina and 39 more
- Volunteers
- 379 people
- Sponsor
- Pfizer
HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
- Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
- Trial name
- NCT07037277
- Testing
- Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir
- Where
- 107 sites in Egypt, France and 15 more
- Volunteers
- 880 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Hereditary Angioedema (HAE)
A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt
Hereditary angioedema (HAE) is a rare condition. It causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. This swelling happens because of a temporary leak in blood vessels.
- Trial name
- EXPLORHAE (NCT07218393)
- Testing
- No intervention
- Where
- 7 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Takeda
Metastatic Breast Cancer
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
The objective of this non-interventional multicenter study is to provide prospective, observational data on patients initiating treatment with palbociclib combination to contribute to the knowledge of HR+ HER2-metastatic/locally…
- Trial name
- PRECIOUS (NCT04937660)
- Where
- 12 sites in Egypt, Jordan and 3 more
- Volunteers
- 185 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
This randomized, active controlled, multicenter phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with crizotinib treatment in participants with treatment-naive anaplastic lymphoma…
- Trial name
- ALEX (NCT02075840)
- Testing
- Alectinib, Crizotinib
- Where
- 97 sites in United States, Australia and 27 more
- Volunteers
- 303 people
- Sponsor
- Hoffmann-La Roche